Some of the identified Tau-targeting peptides were able to penetrate neuronal cells, reduce Tau phosphorylation or improved cognitive abilities of Tau transgenic mice, making them interesting for AD therapy. The gene discussed is MAPT; the disease is Alzheimer disease.